普瑞巴林治疗老年带状疱疹后遗神经痛的临床疗效观察  

Observation on clinical efficacy of pregabalin in the treatment of postherpetic neuralgia in the elderly

作　　者：阴亚坤[1] 赵滨 焦晓燕 蔡丙杰[1] YIN Ya-kun;ZHAO Bin;JIAO Xiao-yan;CAI Bing-jie(Department of Dermatology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Dermatology,The Third People s Hospital of Henan Province,Zhengzhou 450000,China)

机构地区：[1]郑州大学第一附属医院皮肤科,河南郑州450052 [2]河南省直第三人民医院皮肤科,河南郑州450000

出　　处：《皮肤性病诊疗学杂志》2019年第6期332-335,共4页Journal of Diagnosis and Therapy on Dermato-venereology

摘　　要：目的:探讨普瑞巴林治疗老年带状疱疹后遗神经痛的有效性和安全性。方法:将62例老年带状疱疹后遗神经痛患者随机分为观察组(32例)和对照组(30例),对照组给予口服甲钴胺胶囊和维生素B 1片,均为1天3次,1次1片;观察组在对照组用药基础上给予普瑞巴林胶囊口服,初始剂量1天2次,1次75 mg,若疼痛控制不理想,可加量至1天2次,每次150 mg,也可根据服药后患者疼痛缓解程度适当减量。两组疗程均为2周。治疗前、治疗第1周和治疗第2周后分别观察两组患者的VAS评分、DLQI评分和治疗后的不良反应。结果:观察组患者治疗后第1周、第2周的VAS评分和DLQI评分均较治疗前降低,差异均具有统计学意义(P值均<0.01);且第2周的VAS评分和DLQI评分比第1周下降更明显,差异有统计学意义(P值均<0.05);对照组治疗后第1周、第2周的VAS评分和DLQI评分较治疗前差异均无统计学意义(P值均>0.05)。观察组患者出现嗜睡、头晕、口干、便秘等不良反应,但均未影响治疗;两组均未见其他明显不良反应。结论:普瑞巴林治疗老年带状疱疹后遗神经痛安全有效。Objective:To investigate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in the elderly.Methods:Sixty-two patients with postherpetic neuralgia in our department were randomly divided into observation group(32 cases)and control group(30 cases).The control group received routine treatment,oral mecobalamin capsules and vitamin B 1 tablets,three times a day,one tablet for once,for 2 weeks.The observation group was given orally with pregabalin capsule on the basis of the control group,the initial dose was 75 mg twice a day.If the pain control was not satisfactory,the dosage could be increased to 150 mg twice a day,or reduced appropriately according to the degree of pain relief after taking the drug.The course of treatment was 2 weeks.The VAS,DLQI score and adverse reactions were observed before treatment,in the first week and the second week after treatment.Results:The VAS and the DLQI score in the first week and in the second week after treatment in the observation group were lower than those before treatment,and the difference was statistically significant(P<0.01).The VAS and the DLQI score in the second week decreased more significantly than those in the first week(P<0.05).The VAS and the DLQI score in the control group in the first week and in the second week after treatment had no significant difference compared with those before treatment(P>0.05).The patients in the observation group had adverse reactions such as drowsiness,dizziness,dry mouth and constipation,but none of them affected the treatment.No other obvious adverse reactions was observed in the two groups.Conclusion:Pregabalin is safe and effective in the treatment of postherpetic neuralgia in the elderly.

关 键 词：普瑞巴林 老年 带状疱疹后遗神经痛 

分 类 号：R752.1[医药卫生—皮肤病学与性病学]